The Effect of Dexmedetomidine, Melatonin and Pregabalin

Sponsor
Egymedicalpedia (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05829148
Collaborator
(none)
120
1
4
18.7
6.4

Study Details

Study Description

Brief Summary

Various drugs have been used for the purpose: nitroglycerine, sodium nitroprusside, propofol, beta blockers, calcium channel blockers, higher concentrations of inhalational anesthetics etc. Since all these drugs have certain limitations there was a search for more safe and effective drug

Condition or Disease Intervention/Treatment Phase
Early Phase 1

Detailed Description

Functional Endoscopic Sinus Surgery (FESS) is done via endoscope and the area is highly vascular thus it becomes important to minimize bleeding, hence we require hypotensive anesthesia.

Dexmedetomidine (a highly selective α2-receptor agonist that has sedative, analgesic, anxiolytic, and opioid sparing effects without significant respiratory depression) it also reduces the need for inhaled anesthetics. dexmedetomidine also minimizes postoperative opioid consumption as well as nausea, vomiting, and anxiety.

Melatonin is a neurohormone mainly secreted from the pineal gland by the suprachiasmatic nucleus. It possesses a circadian secretion pattern and regulates the biological clock; it also offers antiemetic, analgesic, and anxiolytic effects. Due to its effect on both acute and chronic pain, melatonin (available in 5mg tablet form) fulfills a beneficial role in reducing postoperative opioid consumption while minimizing nausea and vomiting.

Pregabalin, whose structure is similar to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), possesses analgesic and anxiolytic activities and is effective in alleviating the neuropathic component of acute nociceptive pain of surgery. It has also been used as premedication to attenuate the hemodynamic stress response to laryngoscopy and intubation and to decrease intraoperative anesthetic requirement

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Comparison Between the Effect of Dexmedetomidine, Melatonin and Pregabalin on Hypotensive Anesthesia in Patients Undergoing Functional Endoscopic Sinus Surgery
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2024
Anticipated Study Completion Date :
Nov 20, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Dexmedetomidine Group

This Group about 30 patients will receive dexmedetomidine loading dose 1 µg/kg over a period of 15 minutes and maintenance 0.2µg/kg/h throughout the surgery .

Drug: Dexmedetomidine
Comparison the effect of Dexmedetomidine, Melatonin and Pregabalin on hemodynamics, recovery profile and postoperative pain in patients undergoing Functional endoscopic sinus

Active Comparator: Melatonin Group

This Group about 30 patients will receive 10 mg melatonin (2 tablets) one hour before starting of the operation.

Drug: Melatonin
Melatonin

Active Comparator: Pregabalin Group

This Group about 30 patients will receive oral pregabalin 150 mg one hour before starting of the operation..

Drug: Pregabalin
Pregabalin

Placebo Comparator: Control Group

This Group about 30 patients will receive oral starch tablet as a control. Heart rate (HR) and blood pressure values will be recorded at various intervals.

Drug: Placebo
Placebo

Outcome Measures

Primary Outcome Measures

  1. Pain Relieve [2 hours post operative]

    Assessment of the pain post-operatively in patients with pain score by VAS as : Total scores vary from 0 to 10 in this method, with a higher score indicating more severe pain,

Secondary Outcome Measures

  1. controlled pulse rate [From base line to 1 hour after the end of the operation]

    Hemodynamics stability

  2. controlled blood pressure [From base line to 1 hour after the end of the operation]

    Hemodynamics stability

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients undergoing Functional endoscopic sinus surgery (ASA I & II)
Exclusion Criteria:
  • Hepatic, renal, endocrinal, hematological disorders.

  • BMI>30 kg/m2.

  • Patients receiving magnesium supplementation, anticonvulsant drugs or antipsychotic drugs.

  • Chronic use of opioids.

  • Current treatment with β-blocker or calcium channel blocker.

  • Known allergies to any of study drugs.

  • Patients refusal to the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Al-Azhar University hospitals Cairo Egypt

Sponsors and Collaborators

  • Egymedicalpedia

Investigators

  • Study Chair: Mohamed AbdelGawad, Assist.Prof, Al-Azhar University, Faculty of medicine for boys

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Egymedicalpedia
ClinicalTrials.gov Identifier:
NCT05829148
Other Study ID Numbers:
  • Alaa Abdel-Khalek
First Posted:
Apr 25, 2023
Last Update Posted:
Apr 25, 2023
Last Verified:
Apr 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 25, 2023